Arcutis logo.png
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
13 nov. 2024 08h00 HE | Arcutis Biotherapeutics, Inc.
ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4...
Arcutis logo.png
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
06 nov. 2024 16h00 HE | Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter ended September 30, 2024, and provided a business update.
Arcutis logo.png
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 nov. 2024 16h00 HE | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis logo.png
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
24 oct. 2024 08h00 HE | Arcutis Biotherapeutics, Inc.
Arcutis today announced new patient-reported outcome data demonstrating that ZORYVE cream 0.15% improved the impact of AD on patients and families.
Arcutis logo.png
Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference
23 oct. 2024 16h00 HE | Arcutis Biotherapeutics, Inc.
Quarterly investor conference call and webcast is scheduled for Wednesday, November 6 at 4:30 p.m. ETArcutis management will also participate in the Guggenheim Securities Healthcare Innovation...
Arcutis logo.png
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
18 oct. 2024 08h20 HE | Arcutis Biotherapeutics, Inc.
Arcutis today announced regulatory approval from Health Canada for ZORYVE (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis.
Arcutis logo.png
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 oct. 2024 16h00 HE | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis logo.png
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
25 sept. 2024 01h00 HE | Arcutis Biotherapeutics, Inc.
Arcutis today announced new pooled subgroup analysis results from the Phase 3 INTEGUMENT-1 and -2 trials.
Arcutis logo.png
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
24 sept. 2024 08h00 HE | Arcutis Biotherapeutics, Inc.
Arcutis today announced the FDA has accepted its sNDA for ZORYVE (roflumilast) foam 0.3% for scalp and body psoriasis.
Arcutis logo.png
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
19 sept. 2024 08h00 HE | Arcutis Biotherapeutics, Inc.
ZORYVE® (roflumilast) cream 0.15% improved atopic dermatitis (AD) across multiple efficacy endpoints while demonstrating favorable safety and tolerabilityAcross both studies, approximately 31% of...